Related Experiment Video
Updated: Sep 9, 2025

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer
Published on: March 14, 2019
Polymerase-based DNA reactions for molecularly computing cancerous diagnostic valences of multiple miRNAs
Yumin Yan1,2, Hongyang Zhao2, Lijie Xing3
1Key Laboratory of Agro-food Safety and Quality of Ministry of Agriculture and Rural Affairs, Institute of Quality Standard and Testing Technology for Agro-Products, Chinese Academy of Agricultural Sciences, Beijing, 100081, China.
Abstract:
Conventional miRNA-based diagnostic methods often treat all biomarkers equally, overlooking the fact that each miRNA contributes differently to disease classification. This differential diagnostic importance is captured by the concept of Cancerous Diagnostic Valence (CDV)-a metric that quantifies both the direction (oncogenic or protective) and magnitude of each miRNA's association with cancer. Here, we introduce a polymerase-based DNA molecular computing system that directly encodes and integrates CDVs to perform weighted molecular classification of non-small cell lung cancer (NSCLC). By coupling DNA polymerase-mediated strand extension and displacement (PB-DSD and cascade PB-DSD), the system translates miRNA inputs into proportional molecular signals spanning a wide CDV range (1-25), with minimal probe complexity. Seven NSCLC-related miRNAs with machine learning-derived CDVs were used to construct a diagnostic classifier, achieving 95% accuracy in tissue and 90% in plasma samples. Compared to conventional toehold strand displacement systems, this approach offers broader scalability, lower background interference, and more accurate diagnostic logic. Furthermore, we demonstrate its utility for therapeutic monitoring by tracking drug-induced shifts in CDV-weighted miRNA profiles in tumor-bearing mice treated with allicin and curcumin. This work establishes a molecularly programmable and biologically informed diagnostic platform that advances the precision and interpretability of miRNA-based cancer diagnostics.

